Twice-yearly shot proves successful at preventing HIV infection among women, trial data shows

Two shots a year of a drug used to treat HIV infections demonstrated 100% efficacy in preventing infections in a study among young women and adolescent girls in Africa. The drug lenacapavir, administered twice-yearly, provided total protection against HIV infections. This finding suggests that lenacapavir could be an additional option for preventing HIV infections. In a trial involving over 5,000 participants, none of the individuals who received the lenacapavir injections acquired HIV infection. The injections could offer a highly effective, tolerable, and discreet choice for HIV prevention.